Researchers identify avenue for enhanced GLP-1-induced weight loss
Sunday, May 24 – A team of researchers at the National Institutes of Health (NIH) have unveiled new details about the events GLP-1 receptor agonists trigger within neurons, which have been largely unexplored until now. A study in mice identified key intracellular signaling processes that are tied to the weight-loss effects of the GLP-1 drug semaglutide. The work has been published in Nature Metabolism
Ozempic and other GLP-1 RAs could slow progression of some cancers, data suggest
Sunday, May 24 – Real-world data show that GLP-1 receptor agonists (GLP-1s) may reduce metastatic progression of certain obesity-related cancers, namely lung, breast, colorectal, and liver cancers. In addition, GLP-1 receptor (GLP-1R) expression was associated with overall survival, suggesting that GLP-1 signaling could be involved in the progression of these cancers.
Lilly’s oral GLP-1 milestone highlights a steady April for FDA approvals
Sunday, May 24 – The U.S. FDA granted 14 approvals in April 2026, down from March’s 19 but broadly in line with the historical range for the month.
Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds
Sunday, May 24 – Metabolic/bariatric surgery is a highly effective treatment for people living with severe obesity and/or metabolic health conditions, which works through changing the anatomy of the digestive system and thereby changing the way it functions and the hormones it produces. Procedures include the sleeve gastrectomy and gastric bypass.
EU regulator approves pill form of Novo Nordisk’s Wegovy weight loss drug
Novo Nordisk has obtained approval for the pill form of its popular Wegovy anti-obesity drug in the European Union, the bloc’s medicines regulator said on Friday.
GLP-1 Users May Experience A Surprising Life-Saving Benefit That Has Nothing To Do With Weight Loss
A new study found that some cancer patients who took GLP-1 drugs saw some remission — especially if they had breast cancer.
Wegovy linked to rare “eye stroke” that can cause sudden blindness
A new analysis is raising concerns about Wegovy, the blockbuster weight-loss drug, after researchers found it may carry the highest risk of a rare “eye stroke” that can cause sudden vision loss. The study, based on millions of FDA side-effect reports, found the risk signal was nearly five times stronger for Wegovy than for Ozempic, despite both containing semaglutide.
From high BMI to the ‘GLP-1 look’: how weight-loss jabs are changing the face of beauty
Experts say exponential growth in the use of drugs such as Wegovy is shifting our perception of what is attractiveMona Lisa is the most famous portrait ever painted and millions of people flock to the Louvre to admire her enigmatic smile every year.As well as being beautiful, Mona Lisa was, according to some experts, also seriously overweight. Now they are asking how that leaves our notions of artistic beauty in an era of weight-loss drugs such as Wegovy and Mounjaro, arguing that in future, “GLP-1 face” could become the subject of modern depictions of artistic beauty. Continue reading…
People On GLP-1s Are Sharing The 1 Unexpected Obsession They Didn’t Expect
“I thought about it for days.”View Entire Post ›
Lilly’s Triple Agonist, Retatrutide, Delivered Powerful Weight Loss in Pivotal Phase 3 Obesity Trial
Saturday, May 22 – INDIANAPOLIS, May 21, 2026 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy…